media – Page 579 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

AI Biotech XtalPi Closes Series B Round Funding from Sequoia China, Google, and Tencent

XtalPi Inc., a computation-driven pharmaceutical technology company, announced that it has closed a Series B funding round of 15 million USD led by Sequoia China, with participation from Google and existing investor Tencent. To date, XtalPi has raised over 20 million USD, making it one of the top-funded AI-powered biotechs.
- Source: finance.yahoo
- 533
- February 26, 2018
biotechs Market Views Series
Merck Drops $394 Million to Acquire Virus-Based Cancer Company Viralytics

Merck & Company is driving forward in its quest to develop a premier immuno-oncology pipeline. The company plunked down $394 million to acquire Australia-based Viralytics Ltd and its oncolytic immunotherapy treatments.
- Source: Biospace;
- 736
- February 26, 2018
immuno-oncology pipelin immunotherapy Market Views Merk
U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Gilead Sciences, Inc.(NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. Biktarvy combines the novel, unboosted integrase strand transfer inhibitor (INSTI) bictegravir, with the demonstrated safety and efficacy profile of the Descovy® (FTC/TAF) dual nucleoside reverse transcriptase inhibitor (NRTI) backbone, and is the smallest INSTI-based triple-therapy STR available.
- Source: gilead
- 912
- February 26, 2018
Biktarvy FDA Gilead Sciences HIV-1 infection
Choices for Your Ideal Medical Hospital Beds

Nursing facilities and home- and community-based services are important for individuals' well-being and can often prevent the need for acute inpatient hospitalizations, which is why it’s important to choose suitable medical hospital beds. Ddu, the leading global pharmaceutical & medical device B2B online platform, now offers you some suggestions on how to choose your medical hospital beds.
- Source: Ddu
- 986
- February 26, 2018
Ddu College hospital beds
FDA Orders Recall of Drug Dosage mHealth App for Diabetic Patients

The FDA has ordered the recall of a mHealth app that helps people with diabetes determine how much insulin they should inject. The issue points to the continuing challenge of verifying the accuracy of digital health devices and drug dosage apps.
- Source: mHealth Intelligence
- 786
- February 26, 2018
diabetes FDA mHealth Policies
What’s Driving the Global Surgical Robotics Market

According to a new market research report by BIS Research, the global surgical robotics market is expected to reach a value of $12.6 billion by the year 2025.
- Source: marketresearch.com
- 1,260
- February 26, 2018
healthcare technologies and innovations Market Reports Market Views surgical
Using “Nanodrops” to Repair Corneas Could Ultimately Replace Glasses

Quite a number of people develop nearsightedness or farsightedness during their lifetimes. "Nanodrops," a new eye drop developed by Israeli ophthalmologists, has successfully fixed corneas in pig eyes, and could potentially do the same for people.
- Source: Futurism
- 531
- February 26, 2018
eye contact healthcare technologies and innovations medtech Researches
Gut bacteria helps fight off sepsis in mice

Sepsis, a potentially life-threatening complication of infection, is currently treated with antibiotics which kill the infection-causing bacteria. But research out of the University of Pennsylvania spotlights an alternative approach: Delivering certain gut microbes to mice boosted antibody levels in mice, protecting them against the widespread inflammation that can lead to sepsis.
- Source: fiercebiotech
- 549
- February 24, 2018
antibiotics Researches sepsis
Priority review for Shire’s HAE drug

US regulators are undertaking a speedy review of Shire’s lanadelumab (SHP643) for the prevention of angioedema attacks in patients 12 years and older with hereditary angioedema (HAE).
- Source: pharmatimes
- 792
- February 24, 2018
angioedema HAE Market Views
Novartis’ Ultibro Breezhaler reduces lung hyperinflation in COPD patients

Treatment with Novartis’ Ultibro Breezhaler significantly boosted lung and cardiac function in chronic obstructive pulmonary disease (COPD) patients with lung hyperinflation, trial findings show.
- Source: Pharmatimes
- 615
- February 24, 2018
Company Insight COPD Ultibro Breezhaler

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.